PharmacoEconomics & Outcomes News 804, p5 - 2 Jun 2018 Adjunctive stiripentol not cost effective in Canada At its current price, adjunctive stiripentol does not appear to be cost effective for the treatment of Dravet syndrome in Canada, according to findings of a cost- utility study published in Pharmacoeconomics. In Canada, stiripentol is approved for use in conjunction with clobazam and valproate in patients with Dravet syndrome whose seizures are resistant to treatment with clobazam and valproate alone. This study used a Markov model to evaluate the cost effectiveness of stiripentol as an adjunctive treatment to clobazam and valproate, compared with clobazam and valproate alone in children with inadequately controlled Dravet syndrome, from the perspective of the Canadian public healthcare payer over a 10-year time horizon. Patients were assumed to receive the maximum recommended Health Canada-approved dosage of each drug. Adjunctive stiripentol was estimated to achieve an incremental gain of 0.60 QALYs compared with clobazam and valproate alone, at an incremental cost of $91 080, resulting in an estimated incremental cost- effectiveness ratio of $151 310 per QALY gained. Drug costs accounted for 72% of total costs of adjunctive stirpentol ($99 062); other healthcare costs were $7982 lower with than with clobazam and valproate alone. At a willingness-to-pay threshold of $50 000 per QALY gained, the probability that stiripentol was the optimal treatment was only 5.2%. The cost of stiripentol would need to be reduced by 61.4% for it to become cost effective. "Stiripentol is currently funded in several Canadian provinces through special access programs. Although confidential agreements with manufacturers may have resulted in reduced prices, the price would need to be reduced by at least 60% to ensure that funding of stiripentol would not lead to a reduction in overall population health. Thus, the decision to cover stiripentol should be reconsidered in light of the likely high opportunity costs of this coverage," commented the authors. * 2017 Canadian dollars Elliot J, et al. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost- Utility Analysis. PharmacoEconomics : 15 May 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0669-7 803322333 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera